EU CONFERENCE ON ENDOCRINE DISRUPTORS
Criteria for Identification and Related Impacts

Potential Impacts Regarding Human Health Risk Assessment

Andreas Hensel
One Substance – One Toxicological Assessment!

But:  
- different regulations for chemical substances  
- different data requirements (from all *in vivo* to *in vitro* only)  
- different regulatory outcomes (from ban to not yet regulated)

|---------------------------------------|--------------------------------|---------------------|---------------------------------------|-------------------------|----------------|

Are data requested under the regulation sufficient for identification?

| ✓ | ✓ | (✓) depending on production volume | (✓) depending on migration from material | (✓) depending on intended use | usually no product specific toxicological data from manufacturers for the authorities available |

What are the principle(s) of regulation?

| Approval procedure | Approval (EU lists of approved additives: AII/III) | Registration, authorisation | Risk assessment + authorisation (EU list of authorised substances) | Risk assessment + inclusion in a list of prohibited/restricted or allowed substances | Risk assessments General provisions |

What are regulatory consequences for substances identified as endocrine disruptors?

| Ban | Authorisation required | Assessment, if criteria approved | not yet regulated |
Principles for Evaluation for Human Health of Substances with Effects on the Endocrine System

**Category 1: Endocrine disruptors**
- sufficient weight of evidence for **adverse effects** in humans at generally low dose levels with high regulatory concern for a hazard-based management approach.

**Category 2: Suspected endocrine disruptors**
- sufficient weight of evidence for **endocrine-mediated effects** in humans at generally moderate dose levels for a risk-based management approach.

**Category 3: Endocrine active substances**
- some evidence that substances affect the endocrine system, but **insufficient evidence for effects in intact organisms.**
- **Further examination** may eventually lead to allocation into Category 1 / 2 or even dispense from grouping.
Principles for Grouping for Human Health of Substances with Effects on the Endocrine System

- Considering the **complexity of the matter**, it is inappropriate to base grouping on the outcome of individual tests.
- Rather, **weight of evidence considerations and expert judgement** should be used case-by-case to decide on the grouping.
- Provided substances have undergone **comprehensive evaluation**.
- Current testing and assessment methodologies are generally suitable to derive **dose/concentration levels which can be considered safe**.
- There is no convincing evidence to assume that **levels of uncertainty** are generally different for EDs compared to other toxic substances.
- Based on **considerations on specificity, severity, reversibility, potency and consistency** of all effects **in a decision matrix** grouping of substances falling under the WHO/IPCS definition **is possible**.
IPCS Definition of Endocrine Disruption

An ED is an exogenous substance or mixture that alters function(s) of the endocrine system and consequently causes adverse health effects in an intact organism, or its progeny, or (sub)populations (WHO/IPCS 2002).

IPCS Definition of Adversity

A change in morphology, physiology, growth, development or lifespan of an organism which results in impairment of functional capacity or increased susceptibility to stress or increased susceptibility to the harmful effects of other environmental influences (WHO/IPCS 2004).
Option 1: No policy change: Interim criteria continue to apply. Should not be applied in praxis.

Option 2: Hazard identification based on the WHO/IPCS definition. Prerequisite, no stand-alone decision criterion.

Option 3: Hazard identification and categories based on strength of evidence. Scientifically not sufficient.

Option 4 (b), missing in the roadmap: Hazard identification and hazard characterisation including severity of effects, reversibility, consistency and potency (adapted from Kortenkamp et al. 2010).

ROADMAP: 4 Options for Criteria
### Outcome of the BfR Impact Assessment Regarding Human Health Risk Assessment

**Option 1:**
- Not applicable
- Not reproducible
- 5 - 10% of substances cut-off
- Not specific for ED, high number of false positive or negative decisions

**Option 2**
- Better applicability
- High reproducibility
- ~30% of substances cut-off
- Low specificity (disregarding scientific information)

**Option 3 (not tested by BfR)**
- Applicability assumed to be low
- Reproducibility assumed to be low
- % cut-off?
- Low specificity assumed due to lack of definition for “strength of evidence”

**Option 4 (b):**
- Best applicability
- High reproducibility
- 5 - 10% of substances cut-off
- High specificity

---

39 pesticide active substances
- reviewed by different scientists
- diverse options for decision making
Potential Impacts for Identification of Endocrine Effects Regarding Human Health Risk Assessment

Option 4 (b):
- Best applicability
- High reproducibility
- 5 - 10 % of substances cut-off
- High specificity

Consequences:
- An **ED decision matrix** is needed, taking into account elements of hazard identification and hazard characterisation, such as
- severity, strength of evidence, reversibility, consistency and potency
- to obtain **reliable, reproducible and transparent** results.
### Decision Matrix for Identification of Endocrine Effects Regarding Human Health Risk Assessment

<table>
<thead>
<tr>
<th>Decision matrix</th>
<th>Cat. 1</th>
<th>Cat. 2</th>
<th>Cat. 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Severity of effect(s)</td>
<td>severe</td>
<td>significant effects</td>
<td>limited effects</td>
</tr>
<tr>
<td>Strength of evidence</td>
<td>sufficient</td>
<td>sufficient</td>
<td>insufficient</td>
</tr>
<tr>
<td>Reversibility of effect(s)</td>
<td>(ir)reversible</td>
<td>reversible</td>
<td>not applicable</td>
</tr>
<tr>
<td>Consistency</td>
<td>high</td>
<td>medium-high</td>
<td>low</td>
</tr>
<tr>
<td>Potency for endocrine targets</td>
<td>high</td>
<td>low</td>
<td>not applicable</td>
</tr>
</tbody>
</table>

**Category 1: Endocrine disruptors:** known or presumed human endocrine disruptor

**Category 2: Suspected endocrine disruptors:** suspected human endocrine disruptor

**Category 3: Endocrine active substances**
Final Conclusions on Potential Impacts Regarding Human Health Risk Assessment

Strong support for option 4(b) as proposed by DE in 2013

Impacts:
- need of an **ED decision matrix**
- **reliable, reproducible, transparent**
- **science-based approach**
- **good applicability and acceptance**
- **compliance with international concepts**
- **stop unacceptable interim criteria**
- **high protection of human health**
- **safer use of pesticidal active substances**
Thank you for your attention

Federal Institute for Risk Assessment
Max-Dohrn-Str. 8-10 ● 10589 Berlin, GERMANY
Tel. +49 30 - 184 12 - 0 ● Fax +49 30 - 184 12 - 47 41
bfr@bfr.bund.de ● www.bfr.bund.de